Opthea Limited Sponsored ADR (OPT) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Opthea Limited, listed on NASDAQ and ASX, is advancing its promising treatment, Sozinibercept, which aims to improve vision for millions of patients suffering from wet age-related macular degeneration (AMD). With patents secured until 2034, Sozinibercept presents a substantial market opportunity, potentially revolutionizing a $15 billion global market by enhancing results when used with standard anti-VEGF-A therapies. The company anticipates pivotal trial data in 2025 and is preparing for the potential commercialization of this innovative product.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.
